CAPTOPRIL-12.5 TAB 12.5MG TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

CAPTOPRIL

Mevcut itibaren:

PRO DOC LIMITEE

ATC kodu:

C09AA01

INN (International Adı):

CAPTOPRIL

Doz:

12.5MG

Farmasötik formu:

TABLET

Kompozisyon:

CAPTOPRIL 12.5MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100/500

Reçete türü:

Prescription

Terapötik alanı:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Ürün özeti:

Active ingredient group (AIG) number: 0114954004; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2009-07-23

Ürün özellikleri

0
PRODUCT MONOGRAPH
PR
CAPTOPRIL
CAPTOPRIL TABLETS USP
12.5, 25, 50 AND 100 MG
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR
PRO DOC LTÉE
DATE OF REVISION:
2925, BOUL. INDUSTRIEL
March 7, 2008
LAVAL, QUÉBEC
H7L 3W9
Control number : 111881
1
PRODUCT MONOGRAPH
Pr
CAPTOPRIL
Captopril Tablets USP
12.5, 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Angiotensin-Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Captopril is an angiotensin converting enzyme inhibitor which is used
in the treatment of
hypertension and heart failure.
The mechanism of action of captopril has not yet been fully
elucidated. It appears to lower blood
pressure and be an adjunct in the therapy of congestive heart failure
primarily through
suppression of the renin-angiotensin-aldosterone system; however,
there is no consistent
correlation between renin levels and response to the drug. Renin, an
enzyme synthesized by the
kidneys, is released into the circulation where it acts on a plasma
globulin substrate to produce
angiotensin I, a relatively inactive decapeptide. Angiotensin I is
then converted by angiotensin-
converting enzyme (ACE) to angiotensin II, a potent endogenous
vasoconstrictor substance.
Angiotensin II also stimulates aldosterone secretion from the adrenal
cortex, thereby contributing
to sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II
by inhibition of ACE, a
peptidyldipeptide carboxy hydrolase.
ACE is identical to ‘bradykininase’, and captopril may also
interfere with the degradation of the
vasodepressor peptide, bradykinin. However, the effectiveness of
captopril in therapeutic doses
appears to be unrelated to potentiation of the actions of bradykinin.
Increased concentrations of
bradykinin or prostaglandin E
2
may also have a role in the therapeutic effect of captopril,
especially in low-renin hypertension.
Inhibition of ACE results in decreased plasma angiotensin II and
increased plasma renin activity
(PRA), the latter resulting from loss of negative feedback on renin
rel